Mefloquine-artesunate

Phase 3Small molecule

CCenters for Disease Control and Prevention

Mefloquine-artesunate is one of 61 small molecule programs targeting Plasmodium falciparum malaria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plasmodium Falciparum MalariaActive, not recruiting

MalariaActive, not recruiting

Plasmodium Falciparum MalariaPhase 2/Phase 3

Active, not recruiting

MalariaPhase 3

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

Mefloquine-artesunate

CCenters for Disease Control and Prevention

Phase 3

2 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 8

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Malarone

Medicines for Malaria Venture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pregnancy2 trials

Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil

Terminated·CCenters for Disease Control and Prevention·Phase 4·NCT01082731·6 enrolled

Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)

Terminated·CCenters for Disease Control and Prevention·Phase 4·NCT01107145·16 enrolled

Malaria2 trials

Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru

Completed·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT00373607·522 enrolled

Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT01939886·219 enrolled

Plasmodium falciparum malaria1 trial

Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy

Completed·IInstitute of Tropical Medicine, Belgium·Phase 2/3·NCT00701961·48 enrolled

Plasmodium Falciparum Infection1 trial

Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection

Withdrawn·CCenters for Disease Control and Prevention·Phase 2/3·NCT01082718

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Mefloquine-artesunate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mefloquine-artesunate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mefloquine-artesunate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centers for Disease Control and Prevention company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCenters for Disease Control and Prevention

Mefloquine-artesunate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pregnancy2 trials

Malaria2 trials

Plasmodium falciparum malaria1 trial

Plasmodium Falciparum Infection1 trial

References

Drug Info

Quick Facts

Related News